NMN vs NR — Which NAD+ Supplement Is Better in 2026?
Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) increase NAD+ levels. The debate over which is better has been ongoing since 2013. Here is where the evidence actually stands in 2026.
Quick Verdict
| Factor | NMN | NR |
|---|---|---|
| Human RCTs | Growing (3-5 quality trials) | More established (6-8 trials) |
| Blood NAD+ increase | Confirmed | Confirmed |
| Preferred by | Sinclair (Harvard) | Brenner (NR discoverer) |
| Cost | Higher | Lower |
| Sublingual availability | Yes (faster absorption) | Limited |
The Biology
Both compounds are NAD+ precursors that follow different paths to reach the same endpoint. Current evidence suggests NMN is converted to NR before entering most cells, though some tissues may have direct NMN uptake via the Slc12a8 transporter (Mills et al. 2016, Cell Metabolism).
Key Human Clinical Trials
NMN
- Yoshino et al. 2021 (Science): 250mg/day NMN for 10 weeks significantly increased skeletal muscle NAD+ levels and improved insulin sensitivity in postmenopausal women
- Liao et al. 2021: 300mg NMN daily improved muscle insulin sensitivity and physical performance in older men
NR
- Trammell et al. 2016 (Nature Comm): NR significantly increased blood NAD+ levels in a dose-dependent manner in healthy adults
- Martens et al. 2018: NR supplementation improved aortic stiffness in older adults with elevated blood pressure
The Practical Answer
Both work. The choice comes down to:
- Choose NMN if: you want sublingual delivery, you follow Sinclair protocol, or you prioritize the growing evidence base
- Choose NR if: you want slightly more established human data, lower cost, or you prefer the Brenner-recommended approach
Both benefit significantly from combining with Apigenin 50mg (CD38 inhibitor) which prevents NAD+ degradation and synergizes with either precursor.



